| Literature DB >> 30800478 |
Mitchell B Sally1,2, Darren J Malinoski1,2, Frank P Zaldivar3, Tony Le4, Matin Khoshnevis5, William A Pinette6, Michael Hutchens1, Shlomit Radom-Aizik3.
Abstract
INTRODUCTION: A majority of transplanted organs come from donors after brain death (BD). Renal grafts from these donors have higher delayed graft function and lower long-term survival rates compared to living donors. We designed a novel porcine BD model to better delineate the incompletely understood inflammatory response to BD, hypothesizing that adhesion molecule pathways would be upregulated in BD.Entities:
Keywords: Basic translational research; brain death; donor management; genomic; inflammation; porcine model; transplantation
Year: 2018 PMID: 30800478 PMCID: PMC6374499 DOI: 10.1017/cts.2018.312
Source DB: PubMed Journal: J Clin Transl Sci ISSN: 2059-8661
Fig. 1Diagram of instrumentation of animals in the porcine herniation model. ICP, intracranial pressure
Fig. 2Graphical representation of the physiologic response to inflation of balloon catheter (mimicking a herniation event) in animals. This graph shows time-dependent heart rate and mean arterial pressure measurements, stratified by control and brain death groups. *Statistically significant difference by ANOVA testing.
Selected Kyoto Encyclopedia of Genes and Genomes (KEGG) pathways in porcine model significantly upregulated 6 hours following brainstem herniation when compared with control animals
| KEGG pathway | Number of genes | EASE score | FDR | Role in inflammation and transplantation |
|---|---|---|---|---|
| Antigen processing and presentation | 7 | 7.20E-05 | 7.60E-04 | Associated with macrophage presence in rejected renal allograft specimens [ |
| Toll-like receptor signaling pathway | 8 | 1.00E-04 | 1.00E-03 | Initiate allograft inflammation and promote development of acute and chronic rejection [ |
| TNF-signaling pathway | 8 | 1.50E-04 | 1.40E-03 | Inhibition protects kidney from ischemia-reperfusion injury by reducing accumulation of macrophages/monocytes [ |
| Graft-versus-host disease | 5 | 4.60E-04 | 4.00E-03 | Associated with immune function, chronic inflammation [ |
| Allograft rejection | 5 | 6.40E-04 | 4.40E-03 | Upregulated renal dysfunction in transplant recipients [ |
| Cell adhesion molecules (CAMs) | 8 | 8.50E-04 | 5.40E-03 | Mediate infiltration to graft, disseminate antigenic message to host lymphoid tissue [ |
| Natural killer cell-mediated cytotoxicity | 7 | 1.00E-03 | 5.90E-03 | Play a role in renal transplant loss [ |
| Cytokine-cytokine receptor interaction | 9 | 2.60E-03 | 1.20E-02 | Upregulated in renal dysfunction in transplant recipient [ |
| Jak-STAT signaling pathway | 7 | 4.00E-03 | 1.80E-02 | Upregulated in renal dysfunction in transplant recipients [ |
| PPAR signaling pathway | 5 | 5.80E-03 | 2.50E-02 | Postulated involvement in UC after renal transplant [ |
| Chemokine signaling pathway | 7 | 1.00E-02 | 4.20E-02 | Upregulated in inflammatory states like SCI [ |
EASE, expression analysis systematic explorer; FDR, false discovery rate; Jak-STAT, Janus kinase/signal transducers and activators of transcription; PPAR, peroxisome proliferator-activated receptor; UC, ulcerative colitis; SCI, spinal cord injury; TNF, tumor necrosis factor.
Individual genes in Kyoto Encyclopedia of Genes and Genomes pathways significantly affected 6 hours following brain death when compared with sham group
| Gene name (gene symbol) | FC | Directional change |
|---|---|---|
| Antigen processing and presentation | ||
| MHC class II DR-α (SLA-DRA) | 1.6 | Up |
| MHC class II histocompatibility antigen SLA-DQA (SLA-DQA1) | 1.8 | Up |
| SLA-DQ β1 domain (SLA-DQB1) | 1.6 | Up |
| Major histocompatibility complex, class II, DO α (SLA-DOA) | 1.8 | Up |
| Proteasome activator subunit 2 (PSME2) | 1.7 | Up |
| Transporter 1, ATP-binding cassette, sub-family B (MDR/TAP) (TAP1) | 2.2 | Up |
| Toll-like receptor signaling pathway | ||
| FBJ murine osteosarcoma viral oncogene homolog (FOS) | 3.3 | Up |
| Caspase 8, apoptosis-related cysteine peptidase (CASP8) | 1.8 | Up |
| Chemokine (C-C motif) ligand 4 (CCL4) | 2.4 | Up |
| Chemokine (C-C motif) ligand 5 (CCL5) | 2.7 | Up |
| Interferon (α, β, and ω) receptor 1 (IFNAR1) | 1.8 | Up |
| Interferon regulatory factor 7 (IRF7) | 2.1 | Up |
| Signal transducer and activator of transcription 1, 91 kDa (STAT1) | 1.9 | Up |
| Toll-like receptor-4 (TLR-4) | 1.9 | Up |
| TNF signaling pathway | ||
| FBJ murine osteosarcoma viral oncogene homolog (FOS) | 3.3 | Up |
| Activating transcription factor 4 (ATF4) | 1.6 | Up |
| Caspase 3, apoptosis-related cysteine peptidase (CASP3) | 1.5 | Up |
| Caspase 8, apoptosis-related cysteine peptidase (CASP8) | 1.8 | Up |
| Chemokine (C-C motif) ligand 2 (CCL2) | 14.3 | Up |
| Chemokine (C-C motif) ligand 5 (CCL5) | 2.7 | Up |
| Ribosomal protein S6 kinase α-5 (LOC100152046) | ||
| Vascular cell adhesion molecule 1 (VCAM1) | 3.3 | Up |
| Graft-versus-host disease | ||
| MHC class I antigen 1 (SLA-1) | 1.6 | Up |
| MHC class II DR-α (SLA-DRA) | 1.6 | Up |
| MHC class II histocompatibility antigen SLA-DQA (SLA-DQA1) | 1.8 | Up |
| SLA-DQ β1 domain (SLA-DQB1) | 1.6 | Up |
| Major histocompatibility complex, class II, DO α (SLA-DOA) | 1.8 | Up |
| Allograft rejection | ||
| MHC class I antigen 1 (SLA-1) | 1.6 | Up |
| MHC class II DR-α (SLA-DRA) | 1.6 | Up |
| MHC class II histocompatibility antigen SLA-DQA (SLA-DQA1) | 1.8 | Up |
| SLA-DQ β1 domain (SLA-DQB1) | 1.6 | Up |
| Major histocompatibility complex, class II, DO α (SLA-DOA) | 1.8 | Up |
| Cell adhesion molecules (CAMs) | ||
| MHC class I antigen 1 (SLA-1) | 1.6 | Up |
| MHC class II DR-α (SLA-DRA) | 1.6 | Up |
| MHC class II histocompatibility antigen SLA-DQA (SLA-DQA1) | 1.8 | Up |
| SLA-DQ β1 domain (SLA-DQB1) | 1.6 | Up |
| Integrin, β 2 (complement component 3 receptor 3 and 4 subunit) (ITGB2) | 1.8 | Up |
| Integrin, β 8 (ITGB8) | 2.7 | Up |
| Major histocompatibility complex, class II, DO α (SLA-DOA) | 1.8 | Up |
| Vascular cell adhesion molecule 1 (VCAM1) | 3.3 | Up |
| Natural killer cell-mediated cytotoxicity | ||
| FYN proto-oncogene, Src family tyrosine kinase (FYN) | 1.9 | Up |
| Fc fragment of IgG, low affinity IIIb, receptor (CD16b) (FCGR3B) | 2.0 | Up |
| TYRO protein tyrosine kinase binding protein (TYROBP) | 1.6 | Up |
| Caspase 3, apoptosis-related cysteine peptidase (CASP3) | 1.5 | Up |
| Integrin, β 2 (complement component 3 receptor 3 and 4 subunit) (ITGB2) | 1.8 | Up |
| Interferon (α, β, and ω) receptor 1 (IFNAR1) | 1.8 | Up |
| Protein tyrosine phosphatase, nonreceptor type 6 (PTPN6) | 1.7 | Up |
| Cytokine-cytokine receptor interaction | ||
| Bone morphogenetic protein receptor, type IB (BMPR1B) | ||
| Chemokine (C-C motif) ligand 2 (CCL2) | 14.3 | Up |
| Chemokine (C-C motif) ligand 4 (CCL4) | 2.4 | Up |
| Chemokine (C-C motif) ligand 5 (CCL5) | 2.7 | Up |
| Chemokine (C-C motif) receptor 5 (CCR5) | 1.8 | Up |
| Growth hormone receptor (GHR) | 2.2 | Down |
| Interferon (α, β, and ω) receptor 1 (IFNAR1) | 1.8 | Up |
| Interleukin 10 receptor, β (IL10RB) | 2.7 | Up |
| Transforming growth factor, β 1 (TGFB1) | 2.0 | Up |
| Jak-STAT signaling pathway | ||
| Janus kinase 2 (JAK2) | 2.0 | Up |
| Growth hormone receptor (GHR) | 2.2 | Down |
| Interferon (α, β, and ω) receptor 1(IFNAR1) | 1.8 | Up |
| Interleukin 10 receptor, β (IL10RB) | 2.7 | Up |
| Protein tyrosine phosphatase, nonreceptor type 6 (PTPN6) | 1.7 | Up |
| Signal transducer and activator of transcription 1, 91 kDa (STAT1) | 1.9 | Up |
| Signal transducer and activator of transcription 5A (STAT5A) | 1.6 | Up |
| PPAR signaling pathway | ||
| Angiopoietin-like 4(ANGPTL4) | 6.9 | Down |
| Carnitine palmitoyltransferase 1 A (liver) (CPT1A) | 1.8 | Down |
| Fatty acid binding protein 4, adipocyte (FABP4) | 1.8 | Down |
| Fatty acid binding protein 5 (psoriasis-associated) (FABP5) | 1.7 | Up |
| Glycerol kinase (GK) | 2.1 | Up |
| Chemokine signaling pathway | ||
| Cell division cycle 42 (CDC42) | 1.5901718 | Up |
FC, fold change; TNF, tumor necrosis factor.
Fig. 3Diagrammatic representation of the interactions among genes within the cell adhesion molecule Kyoto Encyclopedia of Genes and Genomes pathway, with significantly upregulated genes in our experiments annotated. *Upregulated in porcine brain death model.
Reverse transcriptase polymerase-chain reaction verification of specific genes in the cell adhesion pathway
| Gene name (gene symbol) | Fold change | Directional change |
|
|---|---|---|---|
| MHC class I antigen 1 (SLA-1) | 1.27 | Up | 0.06 |
| MHC class II DR-α (SLA-DRA) | 1.31 | Up | 0.018 |
| MHC class II histocompatibility antigen SLA-DQA (SLA-DQA1) | 1.34 | Up | 0.05 |
| Integrin, β 2 (complement component 3 receptor 3 and 4 subunit) (ITGB2) | 1.63 | Up | 0.003 |
| Integrin, β 8 (ITGB8) | 1.83 | Up | 4.12E-06 |
| Vascular cell adhesion molecule 1 (VCAM1) | 4.03 | Up | 7.93E-05 |